Prestige Consumer Healthcare Reports Q3 Earnings Decline Amid Strategic Acquisitions and Share Buybacks
PBH sits 17% above its 52-week low of $57.25.
Summary
Prestige Consumer Healthcare reported a significant drop in Q3 net income and EPS, alongside strategic acquisitions, substantial share repurchases, and a notable supplier loan write-off.
Key Events · Earnings and Guidance · PBH
-
Q3 Fiscal 2026 Financial Decline
Net income decreased by 23.5% to $46.7 million, and diluted EPS fell by 20.5% to $0.97 for the three months ended December 31, 2025, compared to the prior year.
-
Strategic Acquisitions Completed
The company acquired Pillar5 Pharma, Inc. for $111.9 million to insource sterile ophthalmic manufacturing for its Clear Eyes brand, and Feminax for $13.9 million, allocating the entire purchase price to intangible assets.
-
Substantial Share Repurchase Activity
Prestige Consumer Healthcare repurchased $45.8 million of common stock in Q3, contributing to a total of $155.6 million in repurchases for the nine months ended December 31, 2025, with $92.9 million remaining under the authorization.
-
Supplier Loan Write-off
A $10.3 million supplier loan was written off during the nine months ended December 31, 2025, impacting other expense, net.
Analysis · PBH · Life Sciences
Prestige Consumer Healthcare Inc. reported a significant decline in its third-quarter and year-to-date fiscal 2026 financial results, with net income falling over 23% and diluted EPS dropping over 20% year-over-year. This negative performance was primarily driven by decreased sales in key categories like Eye & Ear Care and Analgesics, and a notable $10.3 million write-off of a supplier loan. Despite the earnings pressure, the company made strategic moves, including the acquisition of Pillar5 Pharma for $111.9 million to bring ophthalmic manufacturing in-house, and Feminax for $13.9 million. Additionally, the company continued its substantial share repurchase program, buying back $45.8 million in Q3 and $155.6 million year-to-date. The company also expanded its corporate footprint by amending its office lease to add space and extend the term for over a decade, indicating long-term operational commitment. Investors should monitor whether the strategic acquisitions can eventually offset the current financial headwinds and improve profitability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBH was trading at $67.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $57.25 to $90.04. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.